China Post Securities released a research report on April 25 stating that it gave Liberal Arts Biotech (300294.SZ) a purchase rating. The main reasons for the rating include: 1) blood products are expected to maintain good growth, and the amount of pulp collected is expected to increase further throughout the year; 2) excellent profitability, and the products under development are progressing steadily. (Mainichi Keizai Shimbun)
中邮证券4月25日发布研报称，给予博雅生物（300294.SZ）买入评级。评级理由主要包括：1）血制品预计维持良好增长，全年采浆量有望进一步提升；2）盈利能力优秀，在研产品稳步推进。（每日经济新闻）
China Post Securities released a research report on April 25 stating that it gave Liberal Arts Biotech (300294.SZ) a purchase rating. The main reasons for the rating include: 1) blood products are expected to maintain good growth, and the amount of pulp c
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.